Recruiting Fibromyalgia Studies in New York
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofi...
Bionic Pancreas in CFRD
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using...
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF....
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on ...
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection....
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test diffe...
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thro...
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy....
Study of Canakinumab in Patients With Myelofibrosis
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible pat...
About Fibromyalgia Clinical Trials in New York
Fibromyalgia is a condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties. It affects about 2-4% of the population, predominantly women. Treatment includes medications, exercise, stress management, and cognitive behavioral therapy.
There are currently 9 fibromyalgia clinical trials recruiting participants in New York, NY. These studies are seeking a combined 710 participants. Research is being sponsored by Disc Medicine, Inc, Jaeb Center for Health Research, Cumberland Pharmaceuticals and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Fibromyalgia Clinical Trials in New York — FAQ
Are there fibromyalgia clinical trials in New York?
Yes, there are 9 fibromyalgia clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What fibromyalgia treatments are being tested?
The 9 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for fibromyalgia.
Data updated March 2, 2026 from ClinicalTrials.gov